Hrt Financial LP Myovant Sciences Ltd. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$7.78 - $14.69 $572,047 - $1.08 Million	73,528 New	73,528 $913,000
Q1 2022 May 16, 2022	SELL	$11.38 - $16.4 $550,154 - $792,841	-48,344 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $691,802 - $1.15 Million	48,344 New	48,344 $752,000
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $368,177 - $453,114	-17,995 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $248,331 - $497,021	17,995 New	17,995 $497,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.